EQS-News: Successful Annual General Meeting for SCHOTT Pharma: All resolutions approved
|
EQS-News: SCHOTT Pharma AG & Co. KGaA
/ Key word(s): AGM/EGM
Successful Annual General Meeting for SCHOTT Pharma: All resolutions approved
SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, held its Annual General Meeting for fiscal year 2025 today. The shareholders approved all proposed resolutions by a large majority and discharged the Board of Management and the Supervisory Board. The Annual General Meeting also approved the proposed dividend of EUR 0.18 per share, which corresponds to a payout ratio of 18% of consolidated net income. In total, over 95% of the share capital was represented at the Annual General Meeting. The detailed voting results as well as further documents related to the Annual General Meeting are published on the Investor Relations website of SCHOTT Pharma: https://www.schott-pharma.com/investor-relations/events/annual-general-meeting
About SCHOTT Pharma Human health matters. That is why SCHOTT Pharma designs containment solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 30,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,800 people from over 65 nations works at SCHOTT Pharma to contribute to global health. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 986 million in the fiscal year 2025. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment. Further information at www.schott-pharma.com
Press contact: Lea Kaiser Communications Manager +49 (0)6131/66-4073 lea.kaiser@schott.com
03.02.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | SCHOTT Pharma AG & Co. KGaA |
| Hattenbergstraße 10 | |
| 55122 Mainz | |
| Germany | |
| E-mail: | ir.pharma@schott.com |
| Internet: | https://ir.schott-pharma.com/ |
| ISIN: | DE000A3ENQ51 |
| WKN: | A3ENQ5 |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX |
| EQS News ID: | 2270654 |
| End of News | EQS News Service |
|
|
2270654 03.02.2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | ||
| Sales1 | 584,23 | 648,67 | 821,14 | 898,60 | 957,09 | 986,21 | 1.020,00 | |
| EBITDA1,2 | 131,94 | 164,10 | 219,73 | 239,00 | 257,55 | 280,26 | 274,50 | |
| EBITDA-Margin3 | 22,58 | 25,30 | 26,76 | 26,60 | 26,91 | 28,42 | 26,91 | |
| EBIT1,4 | 98,22 | 127,66 | 164,38 | 192,38 | 192,58 | 200,82 | 198,00 | |
| EBIT-Margin5 | 16,81 | 19,68 | 20,02 | 21,41 | 20,12 | 20,36 | 19,41 | |
| Net Profit (Loss)1 | 77,63 | 101,17 | 125,85 | 151,93 | 150,35 | 146,98 | 145,00 | |
| Net-Margin6 | 13,29 | 15,60 | 15,33 | 16,91 | 15,71 | 14,90 | 14,22 | |
| Cashflow1,7 | 104,40 | 132,21 | 182,12 | 181,65 | 225,33 | 179,92 | 184,00 | |
| Earnings per share8 | 0,51 | 0,67 | 0,83 | 1,01 | 0,99 | 0,97 | 0,95 | |
| Dividend per share8 | 0,00 | 0,00 | 0,12 | 0,15 | 0,18 | 0,18 | 0,18 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: KPMG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Schott Pharma | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A3ENQ5 | DE000A3ENQ51 | AG & Co. KGaA | 2.150,78 Mio € | 28.09.2023 | 9F2C268V+9J | |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 13,35 | 22,32 | 0,60 | 16,84 | 2,49 | 11,95 | 2,18 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,15 | 0,18 | 0,18 | 1,26% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 03.02.2026 | 11.02.2026 | 13.05.2026 | 12.08.2026 | 10.12.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -13,26% | -34,98% | -5,43% | -39,44% | -47,11% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
